ethyl 2-phenyl-1,8-naphthyridine-3-carboxylate | 170439-72-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: ethyl 2-phenyl-1,8-naphthyridine-3-carboxylate
• CAS: 170439-72-2
• 化学式: C₁₇H₁₄N₂O₂
• 分子量: 278.31
• InChiKey: IHHVXJPJVOZGSP-UHFFFAOYSA-N

物化性质

• 熔点：
  105 °C(Solv: ethanol (64-17-5))
• 沸点：
  443.1±45.0 °C(Predicted)
• 密度：
  1.211±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  ethyl 2-phenyl-1,8-naphthyridine-3-carboxylate 在 一水合肼 作用下， 以70%的产率得到2-phenyl-1,8-naphthyridine-3-carboxylic acid hydrazide
  参考文献：
  名称：

  Synthesis, Antimicrobial Activities and Molecular Docking Studies of New N-Acylated Derivatives of 5-(2-Phenyl-1,8-naphthyridin-3-yl)-1,3,4-oxadiazol-2-amine

  摘要：

  Present study establishes a novel synthetic route of N-acetylated derivatives of 5-(2-phenyl-1,8-naphthyridine-3-yl)-1,3,4-oxadiazole-2-amine (6a-j), which was achieved in four steps with good yields. 2-Amino nicotinaldehyde and ethyl 3-oxo-3-phenylpropanoate on refluxing with triethylamine in ethanol undergoes Friedlander synthesis to furnish ethyl 2-phenyl-1,8-naphthyridine-3-carboxylate, which further converted into 2-phenyl-1,8-naphthyridine-3-carbohydrazide by reacting with hydrazine hydrate upon reflux, followed by cyclization with cyanogen bromide in the presence of water and 1,4-dioxane with sodium bicarbonate to afford 5-(2-phenyl-1,8-naphthyridin-3-yl)-1,3,4-oxadiazol-2-amine (5). Compound 5 was acetylated using numerous symmetrical anhydrides to synthesize novel N-acetylated derivatives (6a-j). The IR, 1H, 13C NMR and mass spectral analysis were used to characterize the structure of synthetic compounds. The synthesized compounds were evaluated for their antimicrobial efficiency against bacteria (S. aureus and E. coli) using ampicillin as a standard reference and against fungi (C. albicans) using fluconazole as a standard reference. Compound 6e exhibited good antibacterial properties while compounds 6c and 6e had shown high antifungal activity, whereas remaining compounds shown moderate to weaker antimicrobial activity. The synthesized derivatives verified their docking strength against Mtb MurB (PDB ID: 5JZX) and showed significant docking activity, however, compound 6f (-10.98 kcal/mol) and compound 6b (-10.52 kcal/mol) had a strong binding affinity compared to the other synthesized compounds.

  DOI：

  10.14233/ajchem.2024.30953
• 作为产物：
  描述：

  2-氨基-3-吡啶甲醛 、 苯甲酰乙酸乙酯 在 哌啶 作用下， 反应 3.0h， 以84%的产率得到ethyl 2-phenyl-1,8-naphthyridine-3-carboxylate
  参考文献：
  名称：

  [EN] INHIBITORS OF TRKA KINASE
  [FR] INHIBITEURS DE TRKA KINASE

  摘要：

  本发明涉及式I的化合物，该化合物是Tropomyosin-related kinase A（TrkA）的抑制剂：式（I）或其立体异构体、互变异构体或药学上可接受的盐、代谢物、同位素、溶剂合物或前药，其中，Ra、Rb、Rc、Rd、R1、R2、L和Het-Ar如本文所定义。这些化合物可用于预防和/或治疗与神经生长因子（NGF）受体TrkA的异常活动相关的疾病或障碍，如疼痛、炎症或炎症性疾病、癌症、动脉粥样硬化、再狭窄、血栓形成、神经退行性疾病、勃起功能障碍（ED）、皮肤疾病、多发性硬化、干燥综合征、子宫内膜异位症、糖尿病周围神经病变、前列腺炎、传染病、与骨重塑调节失衡相关的疾病、子宫内膜异位症、盆腔疼痛综合征以及由异常组织重塑和纤维化疾病引起的疾病；或与失髓鞘形成或脱髓鞘相关的疾病、障碍、损伤或功能障碍。

  公开号：

  WO2016116900A1

文献信息

• Hydrogen-Transfer-Mediated α-Functionalization of 1,8-Naphthyridines by a Strategy Overcoming the Over-Hydrogenation Barrier
  作者：Xiu-Wen Chen、He Zhao、Chun-Lian Chen、Huan-Feng Jiang、Min Zhang

  DOI：10.1002/anie.201707702

  日期：2017.11.6

  Two become one: A general catalytic hydrogen transfer-mediated α-functionalization of 1,8-naphthyridines is reported for the first time. The pyridyl α-site selectively couples with the C8-site of various tetrahydroquinolines to afford novel tetrahydro-1,8-naphthyridines (see scheme). The reaction features operational simplicity, a readily available catalyst and good functional group tolerance.

  两者合而为一：首次报道了一般的催化氢转移介导的1,8-萘啶的α-官能化。吡啶基α-位点与各种四氢喹啉的C8-位点选择性偶联，得到新颖的四氢-1,8-萘啶（见方案）。该反应具有操作简单，容易获得的催化剂和良好的官能团耐受性的特征。
• Transfer hydrogenative <i>para</i>-selective aminoalkylation of aniline derivatives with N-heteroarenes <i>via</i> ruthenium/acid dual catalysis
  作者：Xiuwen Chen、He Zhao、Chunlian Chen、Huanfeng Jiang、Min Zhang

  DOI：10.1039/c8cc04233k

  日期：——

  simplicity, a readily available catalyst system, excellent functional group tolerance, and exclusive regioselectivity, which offers a significant basis to access novel aniline derivatives that are currently inaccessible or challenging to prepare with conventional approaches, and design new coupling reactions via a hydrogen transfer strategy.

  通过钌/酸双重催化，我们首次提出了苯胺衍生物与N-杂芳烃的转移氢化对位选择性氨基烷基化反应。N-杂芳烃的空间较少受阻的吡啶环的位置2与对位的各种苯胺衍生物偶联氨基，提供了大量的结构修饰的苯胺，一类非常有价值的化合物，具有发现和进一步创建功能分子的潜力。发达的化学特性具有操作简便，易于获得的催化剂体系，出色的官能团耐受性和独特的区域选择性，这为获得目前用常规方法难以获得或具有挑战性的新型苯胺衍生物和设计新的偶联反应提供了重要基础。氢转移策略。
• Substituted heterocyclic compounds and methods of use
  申请人：Hong Fang-Tsao

  公开号：US20060161001A1

  公开（公告）日：2006-07-20

  The present invention relates to nitrogen-containing bicyclic structures and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic β cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

  本发明涉及含氮双环结构及其衍生物，以及其药学上可接受的盐。还包括一种治疗炎症、类风湿性关节炎、帕吉特病、骨质疏松症、多发性骨髓瘤、葡萄膜炎、急性或慢性髓系白血病、胰岛素β细胞破坏、骨关节炎、类风湿脊柱炎、痛风性关节炎、炎症性肠病、成人呼吸窘迫综合症（ARDS）、牛皮癣、克罗恩病、过敏性鼻炎、溃疡性结肠炎、过敏性反应、接触性皮炎、哮喘、肌肉退化、消瘦症、Reiter综合症、1型糖尿病、2型糖尿病、骨吸收性疾病、移植物抗宿主反应、阿尔茨海默病、中风、心肌梗死、缺血再灌注损伤、动脉粥样硬化、脑外伤、多发性硬化症、脑疟疾、败血症、脓毒性休克、毒性休克综合征、发热、因HIV-1、HIV-2、HIV-3、巨细胞病毒（CMV）、流感、腺病毒、疱疹病毒或带状疱疹感染的哺乳动物中，通过给予上述化合物的有效量进行治疗的方法。
• Inhibitors of TrkA kinase
  申请人：GVK BIOSCIENCES PRIVATE LIMITED

  公开号：US10336723B2

  公开（公告）日：2019-07-02

  The present invention is directed to the compounds of Formula I which are inhibitors of tropomyosin-related kinase A (TrkA): Formula (I) or stereoisomers, tautomers or a pharmaceutically acceptable salts, metabolites, isotopes, solvates or prodrugs thereof, wherein, Ra, Rb, Rc, Rd, R1, R2, L and Het-Ar are as defined herein. These compounds can be used for the preventive and/or therapeutic treatment of diseases or disorders associated with abnormal activities of nerve growth factor (NGF) receptor TrkA such as Pain, inflammation or an inflammatory diseases, Cancer, atherosclerosis, restenosis, thrombosis, Neurodegenerative diseases, Erectile Dysfunction (ED), Skin disorders, Autoimmune disease like Multiple sclerosis, Sjögren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis, Infectious diseases, diseases related to an imbalance of the regulation of bone remodeling, endometriosis, pelvic pain syndrome and diseases resulting from abnormal tissue remodelling and fibrotic disorders; or a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination.

  本发明涉及式 I 的化合物，它们是肌球蛋白相关激酶 A（TrkA）的抑制剂：式(I)或其立体异构体、同分异构体或药学上可接受的盐、代谢物、同位素、溶媒或原药，其中，Ra、Rb、Rc、Rd、R1、R2、L 和 Het-Ar 如本文所定义。这些化合物可用于预防和/或治疗与神经生长因子（NGF）受体 TrkA 的异常活动有关的疾病或紊乱，如疼痛、炎症或炎症性疾病、癌症、动脉粥样硬化、血管再狭窄、血栓形成、神经退行性疾病、勃起功能障碍（ED）、皮肤病、自身免疫性疾病（如多发性硬化症、斯约格伦综合征）、子宫内膜异位症、糖尿病周围神经病变、前列腺炎、传染病、与骨重塑调节失衡有关的疾病、子宫内膜异位症、盆腔疼痛综合征以及由异常组织重塑和纤维化紊乱引起的疾病；或与髓鞘脱落或脱髓鞘有关的疾病、失调、损伤或功能障碍。
• Mogilaiah; Reddy, N. Vasudeva, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2002, vol. 41, # 1, p. 215 - 217
  作者：Mogilaiah、Reddy, N. Vasudeva

  DOI：——

  日期：——